Lepu Medical Technology (Beijing) Co., Ltd.

Lepu (Beijing) Medical Devices Co., Ltd. ("Lepu Medical", stock code 300003) was founded in 1999. It is one of the earliest enterprises engaged in the research and development and manufacturing of cardiovascular interventional medical devices in China. It is the only one awarded by the Ministry of Science and Technology. The National Engineering Technology Research Center for Cardiology and Interventional Diagnosis and Treatment Equipment and Equipment, one of the first listed companies on the Growth Enterprise Market in 2009, is one of the few companies in the domestic high-end medical device field that can form strong competition with foreign products. Over the past 20 years, the company has always focused on serving patients with cardiovascular diseases, insisted on R&D and innovation, continued to grow and make breakthroughs in the fields of cardiovascular stents, cardiac pacemakers, cardiovascular drugs and medical artificial intelligence, and undertook many major national scientific research projects, including national Development and Reform Commission high-tech industrialization demonstration project, national science and technology 863 plan development project, science and technology support plan project, etc. At present, the company has developed into a leading domestic high-end medical product industry group of cardiovascular disease implant intervention diagnosis and treatment equipment and equipment, and its business covers four major sectors: medical equipment, pharmaceutical products, medical services and new medical formats. The company adheres to the principle of gradual development of "pre-research generation, registration generation and production and sales generation". Based on coronary drug stents, the company has entered the era of bioabsorbable medical devices and artificial AI intelligent medical devices. The company has international second-generation bioabsorbable stent NeoVas, a new generation of intravascular drug (paclitaxel) eluting balloon catheter Vesselin and other blockbuster products. The internationally leading artificial intelligence AI-ECG ECG analysis software system product has been approved by the US FDA , EU CE certification and NMPA registration and approval, and have a variety of technical characteristics of coronary drug stents, balloons, pacemakers, occluders, heart valves, angiography machines, IVD equipment and diagnostic reagents, surgical instruments, artificial intelligence ECG equipment and household smart medical equipment, etc. In 2020, the Hefei High-tech Cardiovascular Hospital (Gaoxin Hospital) controlled by the company was approved by the Anhui Provincial Health Commission to open an "Internet Hospital". In the future, the company will continue to improve the construction of a full-life cycle industry platform covering the prevention, diagnosis, treatment and rehabilitation of cardiovascular diseases, and strive to create a characteristic ecological platform of “cardiovascular health + anti-tumor” to provide more cardiovascular diseases and Provide advanced products and high-quality services for patients with tumor diseases.